- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Ankylosing spondylitis
- Meeting Date: March 2021
- Public Summary Document (PSD) March 2021 PBAC Meeting - (PDF 1259KB)
- Public Summary Document (PSD) March 2021 PBAC Meeting - (Word 96KB)
Upadacitinib – March 2021
Upadacitinib (ankylosing spondylitis): Tablet 15 mg; Rinvoq®
Last updated
2 July 2021